Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 258

Similar articles for PubMed (Select 17408910)

1.

Prostate cancer screening strategies with re-screening interval determined by individual baseline prostate-specific antigen values are cost-effective.

Kobayashi T, Goto R, Ito K, Mitsumori K.

Eur J Surg Oncol. 2007 Aug;33(6):783-9. Epub 2007 Apr 3.

PMID:
17408910
2.
3.

Cost-benefit analysis of total, free/total, and complexed prostate-specific antigen for prostate cancer screening.

Ellison L, Cheli CD, Bright S, Veltri RW, Partin AW.

Urology. 2002 Oct;60(4 Suppl 1):42-6.

PMID:
12384162
4.

Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.

Bermúdez-Tamayo C, Martín Martín JJ, González Mdel P, Pérez Romero C.

Urol Int. 2007;79(4):336-44.

PMID:
18025853
5.
6.

Economic evaluation of prostate cancer screening with prostate-specific antigen.

Imamura T, Yasunaga H.

Int J Urol. 2008 Apr;15(4):285-8. doi: 10.1111/j.1442-2042.2008.02013.x. Review.

PMID:
18380812
7.

The socioeconomic implications of prostate-specific antigen screening.

Benoit RM, Naslund MJ.

Urol Clin North Am. 1997 May;24(2):451-8. Review.

PMID:
9126243
8.
9.

Prostate cancer, the PSA test and academic detailing in Australian general practice: an economic evaluation.

Stone CA, May FW, Pinnock CB, Elwood M, Rowett DS.

Aust N Z J Public Health. 2005 Aug;29(4):349-57.

PMID:
16222933
10.

Early detection of prostate cancer. Part II: Estimating the risks, benefits, and costs. American College of Physicians.

Coley CM, Barry MJ, Fleming C, Fahs MC, Mulley AG.

Ann Intern Med. 1997 Mar 15;126(6):468-79.

PMID:
9072935
11.

A preliminary model-based assessment of the cost-utility of a screening programme for early age-related macular degeneration.

Karnon J, Czoski-Murray C, Smith K, Brand C, Chakravarthy U, Davis S, Bansback N, Beverley C, Bird A, Harding S, Chisholm I, Yang YC.

Health Technol Assess. 2008 Jun;12(27):iii-iv, ix-124.

12.

Cost-effectiveness of Prostate Health Index for prostate cancer detection.

Nichol MB, Wu J, Huang J, Denham D, Frencher SK, Jacobsen SJ.

BJU Int. 2012 Aug;110(3):353-62. doi: 10.1111/j.1464-410X.2011.10751.x. Epub 2011 Nov 11.

PMID:
22077934
13.

The cost-effectiveness of cervical screening in Australia: what is the impact of screening at different intervals or over a different age range?

Anderson R, Haas M, Shanahan M.

Aust N Z J Public Health. 2008 Feb;32(1):43-52. doi: 10.1111/j.1753-6405.2008.00165.x.

PMID:
18290913
14.

Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.

Ross KS, Carter HB, Pearson JD, Guess HA.

JAMA. 2000 Sep 20;284(11):1399-405.

PMID:
10989402
16.

Update on PSA testing.

Gonzalgo ML, Carter HB.

J Natl Compr Canc Netw. 2007 Aug;5(7):737-42. Review.

PMID:
17692178
17.

Cost effectiveness of risk-prediction tools in selecting patients for immediate post-prostatectomy treatment.

Zubek VB, Konski A.

Mol Diagn Ther. 2009;13(1):31-47. doi: 10.2165/01250444-200913010-00006.

PMID:
19351214
18.

Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.

Shimizu F, Igarashi A, Fukuda T, Kawachi Y, Minowada S, Ohashi Y, Fujime M.

Jpn J Clin Oncol. 2007 Oct;37(10):763-74. Epub 2007 Oct 22.

19.
20.

Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.

Kwon JS, Lu KH.

Obstet Gynecol. 2008 Jul;112(1):56-63. doi: 10.1097/AOG.0b013e31817d53a4.

PMID:
18591308
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk